

Chiara Rosso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/726627/publications.pdf>

Version: 2024-02-01

88
papers

3,916
citations

159585

30
h-index

133252

59
g-index

88
all docs

88
docs citations

88
times ranked

5783
citing authors

#	ARTICLE	IF	CITATIONS
1	Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?. <i>Gut</i> , 2022, 71, 382-390.	12.1	113
2	Hepatocyte-Specific Deletion of HIF2 β Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 459-482.	4.5	13
3	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
4	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 635.	2.4	12
5	Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. <i>Journal of Pathology</i> , 2022, 257, 82-95.	4.5	12
6	Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. <i>Biomedicines</i> , 2022, 10, 792.	3.2	4
7	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 596-606.	3.7	38
8	Performance of cytokeratin-18 apoptotic fragment for the identification of hepatic fibrosis and inflammation in patients with chronic viral hepatitis: a meta-analysis. <i>Minerva Biotechnologica</i> , 2021, 32, .	1.2	3
9	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	2.8	4
10	Analytical and clinical comparison between two different chemiluminescent enzyme immunoassays for the measurement of C-peptide in serum. <i>Minerva Biotechnology and Biomolecular Research</i> , 2021, 33, .	0.5	0
11	Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. <i>Metabolites</i> , 2021, 11, 155.	2.9	44
12	Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101611.	1.5	0
13	Inflammatory Bowel Disease Nurseâ€™ Practical Messages. <i>Nursing Reports</i> , 2021, 11, 229-241.	2.1	8
14	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	3.7	24
15	Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progression. <i>Minerva Gastroenterology</i> , 2021, , .	0.5	0
16	A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. <i>Life</i> , 2021, 11, 650.	2.4	1
17	Is the pattern of liver disease etiology changing in China?. <i>Minerva Medica</i> , 2021, 112, 521.	0.9	0
18	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohnâ€™s Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3387.	2.4	16

#	ARTICLE	IF	CITATIONS
19	Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3257.	2.4	2
20	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
21	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.	3.7	100
22	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. <i>Journal of Advanced Research</i> , 2021, 33, 183-187.	9.5	16
23	Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 187.	2.6	9
24	Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4961.	2.4	8
25	The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 716533.	3.5	27
26	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	7.3	209
27	Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. <i>Cells</i> , 2020, 9, 28.	4.1	26
28	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2776.	3.7	14
29	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
30	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	4.1	22
31	Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. <i>Journal of Clinical Medicine</i> , 2020, 9, 2353.	2.4	18
32	Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1289-1292.	0.4	9
33	Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2020, 7, 616212.	2.6	2
34	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	3.7	27
35	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2489-2499.	3.9	9
36	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 800.	2.4	29

#	ARTICLE	IF	CITATIONS
37	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114985.	1.8	14
38	Moving towards core antigen for the management of patients with overt and occult HBV infection. <i>Panminerva Medica</i> , 2020, , .	0.8	4
39	Molecular mechanisms of hepatic fibrosis in chronic liver diseases. <i>Minerva Biotecnologica</i> , 2020, 32, .	1.2	33
40	Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease. <i>Clinical Laboratory</i> , 2020, 66, .	0.5	5
41	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	3.7	128
42	PS-205-Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease: An international study in non-cirrhotic, biopsy-proven patients. <i>Journal of Hepatology</i> , 2019, 70, e136-e137.	3.7	1
43	THU-464-NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha. <i>Journal of Hepatology</i> , 2019, 70, e363-e364.	3.7	0
44	THU-208-Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA. <i>Journal of Hepatology</i> , 2019, 70, e254-e255.	3.7	1
45	Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation. <i>Digestive and Liver Disease</i> , 2019, 51, 1400-1408.	0.9	31
46	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.	4.4	66
47	Non-invasive markers to detect colorectal cancer in asymptomatic population. <i>Minerva Biotecnologica</i> , 2019, 31, .	1.2	6
48	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6333.	4.1	24
49	Serum zonulin in patients with inflammatory bowel disease: a pilot study. <i>Minerva Medica</i> , 2019, 110, 95-100.	0.9	66
50	Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. <i>Minerva Medica</i> , 2019, 110, 401-409.	0.9	22
51	Physiopathology of intestinal barrier and the role of zonulin. <i>Minerva Biotecnologica</i> , 2019, 31, .	1.2	66
52	Diagnosis of <i>Helicobacter pylori</i> infection: a look into molecular aspects of urea breath test. <i>Minerva Biotecnologica</i> , 2019, 31, .	1.2	12
53	Hypoxia-inducible factor 2 α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. <i>Hepatology</i> , 2018, 67, 2196-2214.	7.3	66
54	Usefulness of the index of NASH vs ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018, 38, 715-723.	3.9	22

#	ARTICLE	IF	CITATIONS
55	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018, 67, 145-158.	7.3	296
56	Laboratory evidence of <i>Helicobacter</i> species infection in hepatocellular carcinoma. <i>Minerva Biotecnologica</i> , 2018, 30, .	1.2	13
57	Fecal calprotectin: beyond intestinal organic diseases. <i>Panminerva Medica</i> , 2018, 60, 29-34.	0.8	41
58	Basic and clinical aspects of resistin. <i>Minerva Biotecnologica</i> , 2018, 30, .	1.2	5
59	Role of miR-503 in gastric cancer. <i>Panminerva Medica</i> , 2018, 60, 227-228.	0.8	1
60	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017, 37, 1389-1396.	3.9	44
61	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1277-1286.	0.4	38
62	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	2.8	43
63	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
64	Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated interferon- α . <i>Hepatology Research</i> , 2017, 47, 747-754.	3.4	20
65	Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clobopride: a "real world" study by ¹³ C-octanoic Acid Breath Test. <i>Minerva Medica</i> , 2017, 108, 489-495.	0.9	17
66	Liver fibrosis: the 2017 state of art. <i>Panminerva Medica</i> , 2017, 59, 320-331.	0.8	53
67	Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. <i>Panminerva Medica</i> , 2017, 59, 283-289.	0.8	35
68	Chronic Hepatitis B Treatment: Current Perspectives on Telbivudine. <i>İstanbul Medical Journal</i> , 2017, 18, 189-195.	0.1	0
69	Considerations on meta-analyses regarding the association between long non-coding RNA and neoplasms. <i>Minerva Medica</i> , 2017, 109, 68.	0.9	1
70	Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load. <i>International Journal of Molecular Sciences</i> , 2016, 17, 479.	4.1	70
71	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. <i>International Journal of Molecular Sciences</i> , 2016, 17, 717.	4.1	158
72	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0163069.	2.5	63

#	ARTICLE	IF	CITATIONS
73	How to diagnose NAFLD in 2016. <i>Journal of Hepatology</i> , 2016, 65, 643-644.	3.7	36
74	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	7.3	67
75	Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2016, 48, 55-61.	0.9	19
76	The macrophage activation marker <i>CD</i> 163 is associated with morphological disease stages in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1549-1557.	3.9	94
77	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. <i>Annual Review of Medicine</i> , 2016, 67, 103-117.	12.2	535
78	Usefulness of fecal calprotectin determination in pediatric intestinal diseases. <i>Minerva Pediatrica</i> , 2016, 68, 478-486.	2.7	2
79	A Comment on the Letter. <i>Archives of Iranian Medicine</i> , 2016, 19, 886.	0.6	0
80	Chronic hepatitis C virus infection and lymphoproliferative disorders: Mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B-cell non-Hodgkin lymphoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 742-747.	2.8	19
81	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. <i>Annals of Hepatology</i> , 2014, 13, 91-97.	1.5	12
82	Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1419-1424.	1.5	54
83	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.5	112
84	IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 13146.	3.3	20
85	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 311-317.e1.	4.4	30
86	Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with nonalcoholic steatohepatitis and advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1202-1208.	2.8	55
87	Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. <i>Annals of Hepatology</i> , 2013, 13, 91-7.	1.5	1
88	Occult Hepatitis B Virus Infection in Patients With Chronic Hepatitis C Treated With Antiviral Therapy. <i>Hepatitis Monthly</i> , 2012, 12, e7292.	0.2	9